HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Barefoot partner steps in it

This article was originally published in The Tan Sheet

Executive Summary

Coral calcium marketer Kevin Trudeau was found in contempt of court by a Chicago federal court June 29 for violating a 2003 preliminary injunction barring him from promoting false ad claims. FTC established evidence to the court's satisfaction that Trudeau continued to disseminate a letter and infomercial making the claims. The court ordered Trudeau to cease all marketing of coral calcium products and reserves imposing further remedial measures pending a meeting with the parties. FTC initially charged Trudeau, partner Robert Barefoot and their businesses for making claims that coral calcium cures cancer and other diseases last June (1"The Tan Sheet" June 16, 2003, p. 15). Barefoot and two of his firms reached a stipulated settlement in January (2"The Tan Sheet" Jan. 26, 2004, p. 10)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS128661

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel